Up­dat­ed: Roche buys Re­gor’s CDK in­hibitors for $850M up­front amid push to de­vel­op 20 ‘trans­for­ma­tive’ med­i­cines

Roche is spend­ing $850 mil­lion up­front to buy Re­gor Phar­ma­ceu­ti­cals’ suite of next-gen­er­a­tion CDK in­hibitors as it dou­bles down on its strat­e­gy to pri­or­i­tize three …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER